Psyence Biomedical Ltd.
PBM
$5.21
-$0.445-7.88%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 96.07% | 96.07% | 284.30% | 284.30% | -1,835.19% |
| Total Depreciation and Amortization | 1,100.00% | 1,100.00% | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -99.39% | -99.39% | -13,151.14% | -13,151.14% | 62,937.76% |
| Change in Net Operating Assets | 53.34% | 53.34% | 248.31% | 248.31% | -185.27% |
| Cash from Operations | -63.45% | -63.45% | 4.56% | 4.56% | -30.00% |
| Capital Expenditure | 41.38% | 41.38% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -68.97% | -68.97% | -- | -- | -- |
| Total Debt Issued | -100.00% | -100.00% | 39.86% | 39.86% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 4,539.34% | 4,539.34% | -- | -- | -106.68% |
| Cash from Financing | 331.42% | 331.42% | 216.69% | 216.69% | -31.07% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3,188.42% | 3,188.42% | 264.57% | 264.57% | -88.57% |